X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for the research, development and manufacturing of company's product candidates, including AL001 (latozinemab), a progranulin (PGRN) modulator being developed for frontotemporal dementia (FTD) with progranulin mutation.
Lead Product(s): Latozinemab
Therapeutic Area: Neurology Product Name: AL001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cantor Fitzgerald & Co
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 19, 2024
Details:
AL101 (GSK4527226) is an investigational human monoclonal antibody designed to block and downregulate the sortilin receptor. It is being developed for the treatment of early Alzheimer’s disease (AD), including mild cognitive impairment and mild dementia due to AD.
Lead Product(s): GSK4527226
Therapeutic Area: Neurology Product Name: AL101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2024
Details:
AL001 (latozinemab) is an investigational human monoclonal antibody designed to modulate progranulin (PGRN), a key regulator of immune activity in the brain. It is being developed for the treatment of frontotemporal dementia due to a progranulin gene mutation.
Lead Product(s): Latozinemab
Therapeutic Area: Neurology Product Name: AL001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2024
Details:
The net proceeds will be used for the research, development and manufacturing of company's product candidates, including AL001 (latozinemab), a progranulin (PGRN) modulator being developed for frontotemporal dementia (FTD) with progranulin mutation.
Lead Product(s): Latozinemab
Therapeutic Area: Neurology Product Name: AL001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cantor Fitzgerald & Co.
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 17, 2024
Details:
The Company, in collaboration with AbbVie pursuant to the AbbVie Agreement, continues to develop the Company’s AL003 program, which is focused on targeting Triggering Receptor Expressed on Myeloid cells 2 (TREM2), for the treatment of Alzheimer’s disease.
Lead Product(s): AL003
Therapeutic Area: Neurology Product Name: AL003
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $225.0 million Upfront Cash: $205.0 million
Deal Type: Termination June 30, 2022
Details:
AL001 is being studied in Phase 2 trial for the treatment of frontotemporal dementia patients with a C9orf72 mutation (FTD-C9orf72). FTD-C9orf72 is associated with abnormal accumulation of the protein TDP-43.
Lead Product(s): AL001
Therapeutic Area: Neurology Product Name: AL001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
GSK and Alector to co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases, including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson’s disease and Alzheimer’s disease.
Lead Product(s): AL001
Therapeutic Area: Neurology Product Name: AL001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $2,200.0 million Upfront Cash: $700.0 million
Deal Type: Collaboration July 02, 2021
Details:
AL002 is an investigational humanized monoclonal antibody that targets triggering receptor expressed on myeloid cells 2 (TREM2) with the most important genetic links to sporadic Alzheimer’s disease.
Lead Product(s): AL002
Therapeutic Area: Neurology Product Name: AL002
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2021
Details:
AL002 was shown to be well-tolerated in a first-in-human Phase 1 SAD study in healthy volunteers and modulated cerebrospinal fluid biomarkers indicative of brain target engagement.
Lead Product(s): AL002
Therapeutic Area: Neurology Product Name: AL002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2020
Details:
Under the agreement, Innovent will lead the development and commercialization of the molecule in China, including the manufacturing of the product.
Lead Product(s): Anti-SIRP-alpha antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Innovent Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
